- Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 - Phase 3 HDV LIMT-2 (Peginterferon Lambda) Study Enrolling and Dosing - Phase 3 COVID-19 TOGETHER (Peginterferon Lambda) Study Topline Data 1H22 - Zokinvy MAA CHMP Opinion Expected 1H22 - Strong Cash Position of

PALO ALTO, Calif. , Jan. 3, 2022 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David

PALO ALTO, Calif. , Dec. 21, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc.  (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that the